Form 4: UTHR CEO Exercises, Sells Options Under 10b5-1 Plan
Insider Transaction Report
United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, exercised and sold 4,000 common stock options on September 16, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), executed transactions on September 16, 2025.
- Exercised 4,000 stock options at a price of $120.26 per share.
- Sold 1,000 shares of common stock at a weighted average price of $399.281 per share.
- Sold an additional 3,000 shares of common stock at a weighted average price of $400.5937 per share.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan established on May 2, 2025.
- Following these transactions, direct beneficial ownership is 130 shares, with significant indirect holdings through various trusts and a spouse.
- Remaining derivative securities (stock options) beneficially owned directly total 266,000.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While an insider sale might be seen negatively, it was pre-arranged under a 10b5-1 plan, indicating a planned liquidity event rather than a reaction to adverse news. The significant profit margin on the options exercise is a positive for the insider.
Positives
- The sale prices of approximately $399-$400 per share are significantly higher than the exercise price of $120.26, indicating a substantial gain for the insider.
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which suggests a systematic approach to managing equity holdings rather than a reaction to new, non-public information.
Negatives
- The Chairperson & CEO sold 4,000 shares of common stock, reducing direct beneficial ownership.
Future Outlook
The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
Management Comments
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.
Industry Context
This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or competitors. It reflects an individual's equity management strategy.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | Disclosure of a pre-arranged 10b5-1 trading plan for the exercise and sale of equity securities, entered into on May 2, 2025. | 05/02/2025 | Enhances transparency regarding insider trading activities and provides an affirmative defense against insider trading allegations, aligning with SEC regulations. |
Stakeholder Impact
- Shareholders: The sale by a key executive could be interpreted in various ways, but the 10b5-1 plan mitigates concerns about opportunistic selling. The overall impact is likely minimal given the pre-planned nature.
Next Steps
- Continuation of the 10b5-1 trading plan until the earlier of the exhaustion of 294,000 stock options or December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 03/15/2016 | Stock option exercisable date. |
| 05/02/2025 | Date the pre-arranged 10b5-1 trading plan was entered into. |
| 09/16/2025 | Date of stock option exercise and common stock sales. |
| 09/17/2025 | Signature date of the filing. |
| 12/31/2025 | Earliest date for the 10b5-1 trading plan to conclude, if the tranche of options is not exhausted. |
| 03/15/2026 | Expiration date of the tranche of 294,000 stock options. |
Keywords
United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.